Germany's Merck, Broad Institute Agree on Crispr Intellectual Property License Framework
July 18 2019 - 7:59AM
Dow Jones News
By Max Bernhard
German pharmaceuticals company Merck KGaA (MRK.XE) and the Broad
Institute of Massachusetts Institute of Technology and Harvard
University have agreed to offer nonexclusive licenses to Crispr
intellectual property under their respective control for use in
commercial research and product development, the company said
Thursday.
"We believe that key Crispr patent holders should come together
to simplify and open up access, and this agreement is another
example of a partnership that helps maximize and streamline access
to these important scientific tools," said Issi Rozen, Chief
Business Officer of the Broad Institute.
Crispr is a gene-editing technique that uses an enzyme to make
precise changes to genes associated with certain diseases. Merck
holds several patents for the Crispr applications.
Under the deal, Merck's intellectual property for Crispr
technology, will become available royalty-free to non-profit
academic institutions, non-profit business communities and
governmental agencies for internal research.
Write to Max Bernhard at max.bernhard@dowjones.com;
@mxbernhard
(END) Dow Jones Newswires
July 18, 2019 08:44 ET (12:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck KGAA (TG:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck KGAA (TG:MRK)
Historical Stock Chart
From May 2023 to May 2024
